Lupin and Catalyst Pharmaceuticals settle patent litigation on August 26, 2025, involving FDA approval of Firdapse label expansion for pediatric patients and market generic status.
2 reports, 2 independent
Updated Aug 26
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lupin and Catalyst Pharmaceuticals settle patent litigation on August 26, 2025, involving FDA approval of Firdapse label expansion for pediatric patients and market generic status.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Lupin Pharmaceuticals (United States)
company in Baltimore, United States
Nothing else this week.
-
Catalyst Pharmaceuticals
company in Coral Gables, United States
Nothing else this week.
- FDA
Related events
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- FDA approves generic drug market entry, with Lanreotide challenging Somatuline Depot market share.
- The FDA has not approved a drug for market, and expert practice related to the drug is based in New York.
Coverage
Newest first; wire copies grouped- ZacksCatalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin
- GlobeNewswireCatalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE